Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- New data suggest that millions of patients most at-risk for life-threatening kidney disease are unaware they have it because they are not tested according to clinical practice guidelines despite their risk. The study, by authors from the National Kidney Foundation (NKF) and Labcorp, appears today in the journal Diabetes Care.

National Kidney Foundation and Labcorp Data Show Millions Aren't Tested for Kidney Disease

Quest Diagnostics ( DGX , Financial) shares are trading near a 52-week high of $143.64 as of the writing of this article, boosted by outstanding revenue growth in the second quarter and an encouraging forecast for the full year. The company has a $17.5 billion market cap.

Analysts See Labcorp With Higher Upside Than Quest

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q2 2021 Results - Earnings Call Transcript

LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.

LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised

LabCorp (LH) delivered earnings and revenue surprises of 8.69% and 7.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q2 Earnings and Revenues Beat Estimates

Shares of Laboratory Corp (NYSE:LH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 138.52% over the past year to $6.13, which beat the estimate of $5.57.

Recap: Laboratory Corp Q2 Earnings

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the second quarter ended June 30, 2021, and raised full-year guidance. “Our strategy focusing on science, innovation and technology led to strong second quarter results as we continued to advance health care and patient experiences,” said Labcorp Chairman and CEO Adam Schechter. “Patients and pharmaceutical clients accelerated their return to normal health care and business activi

Labcorp Announces 2021 Second Quarter Results

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth

LH vs. CNMD: Which Stock Is the Better Value Option?

LH vs. CNMD: Which Stock Should Value Investors Buy Now?

Amalgamated Financial Corp

Cigna

America's Car-Mart

D.R. Horton

Federated Hermes

Turtle Beach

Hologic

Lumber Liquidators

Zumiez

To call a beautiful woman a “Perfect 10” these days would be considered chauvinistic and outdated.

The Perfect 10 Portfolio Returned 69% Last Year

Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Hits Fresh High: Is There Still Room to Run?

Clorox

Cabot Oil & Gas

Quest Diagnostics

Gilead Sciences

Merck

Pfizer

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

Academy Sports and Outdoors

Hibbett Sports

Landbridge Co LLC

PetroChina Company Ltd.

Here are five out of the 10 stocks, ASO, LB, PTR, LH, and HIBB, based on hybrid GARP investment strategy.

5 Lucrative Picks Based on PEG Ratio for GARP Investors

LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.

LabCorp (LH) Expands Testing Portfolio With the Launch of CDx

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website. Interested parties can access the conference call by dialing

Labcorp to Announce Second Quarter Financial Results on July 29, 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen. Labcorp's oncology platform brings together the company's leadership in diagnostic testing with its comprehensive drug development services,

Labcorp Launches Companion Diagnostic for Amgen's Newly-approved Lung Cancer Therapy

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy LabCorp (LH) Stock?

The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.

LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research

NEWTON, Mass., June 22, 2021 /PRNewswire/ -- Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples.

Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance

These companies dominate a vital medical industry niche, and their valuations are near their all-time lows.

2 Incredibly Cheap Healthcare Stocks

LabCorp (LH) enables evidence-based, personalized treatment suggestions based on the genomic profiling of a patient's solid tumor with the launch of new test.

News for Labcorp Holdings Inc Stock (LH)